Efficacy of CD19 Directed Therapies in Patients with Relapsed or Refractory Large B-Cell Lymphoma Relapsing after CD19 Directed Chimeric Antigen Receptor T-cell Therapy.

Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and loncastuximab tesirine (loncaT) are approved in R/R LBCL. The efficacy of these CD19 directed therapies in patients who relapse after CD19 directed CAR-T (CD19-CART) therapy is not well understood. We conducted a multi-center study of patients with R/R LBCL that received either tafa-len or loncaT at any timepoint for R/R disease after CD19-CART therapy. Fifty-three patients were included in this study with the median follow up of 56 (9.1–199) weeks from CAR-T infusion. Median number of systemic therapies pre–CAR-T therapy was 3 (range: 1–6); axicabtagene ciloleucel was the most utilized CAR-T product ( n = 32,60%). Median time from CAR-T therapy to tafa-len or loncaT was 7.3 (1.2–38.2) months with median number of lines of therapy between CAR-T therapy and these regimens of 1 (0–5). Combined overall response rate and complete response rates were 27% and 10%, respectively. Median duration of response was 13.3 (2.1–56.7) weeks. In this real-world study, the use of currently approved CD19-directed therapies to treat R/R LBCL after CD19-CAR-T therapy showed limited clinical activity and duration of responses.